Science AI Journal
Medicine · Research topic

Open research questions in Thyroid Cancer Diagnosis and Treatment

737 gap statements mined from Thyroid Cancer Diagnosis and Treatment papers in our 7.9M-paper local library, which holds 2,998 papers on the topic — drawn mostly from each paper's own stated research gap, future-work, challenge and limitation notes, and its abstract. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one.

Choosing where to publish on Thyroid Cancer Diagnosis and Treatment? See the ranked Medicine journals.

What the literature leaves open

  • The study highlights the challenge of managing this condition, including the need for tailored therapeutic strategies. The paper also identifies the challenge of balancing palliative care with aggressive therapy in patients with advanced CRC and poor baseline status.

    Metastatic colorectal carcinoma to the thyroid gland: A case report and literature review · 2026 · DOI

  • The mechanism of calcitonin-negative MTC development and progression is not well understood. The role of ultimobranchial bodies in thyroid cancer development is not fully elucidated. The relationship between C-cell hyperplasia and MTC is not clearly defined.

    Medullary Thyroid Carcinoma Without Calcitonin: A Case Linking Ultimobranchial Bodies to Tumor Evolution · 2025 · DOI

  • Although genetic drivers such as BRAF and TP53 mutations are implicated, the mechanisms underlying this transition remain poorly understood.

    Embryonic reprogramming drives anaplastic transformation in thyroid carcinoma. · 2026 · DOI

  • The ability of Afirma Genomic Sequencing Classifier (GSC) to further risk-stratify indeterminate thyroid nodules among Black and Hispanic patients is understudied.

    The Diagnostic Performance of Afirma Genomic Sequencing Classifier in Black and Hispanic Patients With Indeterminate Thyroid Nodules · 2026 · DOI

  • The extent of central and lateral neck dissection remains controversial, with recommendations largely derived from small series.

    Primary Tumor Location and Lymphatic Spread in Papillary Thyroid Carcinoma · 2026 · DOI

  • How tumor epithelial programs relate to the lymphatic microenvironment remains unclear.

    A SERPINA1-associated SOX4–FN1 epithelial program linked to lymphatic endothelial responses in aggressive papillary thyroid carcinoma · 2026 · DOI

  • However, the efficacy and mechanism of the most potent TMP derivatives against thyroid cancer (TC) remain unclear.

    A novel tetramethylpyrazine derivative inhibits thyroid cancer progression by epigenetically activating the DUSP19-mediated JNK signaling pathway · 2026 · DOI

  • Little is known about patients’ experiences of radioiodine, yet negative beliefs about other novel treatments can influence adherence to precautionary behaviors and side effect experience post treatment.

    Precautionary Behaviors and Side Effects after Radioiodine for Thyroid Disease: A Prospective Cohort Study · 2026 · DOI

  • Larger, prospective studies with extended follow-up are warranted to validate these results, assess long-term outcomes, and compare procedural environments.

    First Clinical Series of Patients Undergoing Nanosecond Pulsed Field Ablation for Symptomatic Benign Thyroid Nodules in a Clinic Setting · 2026 · DOI

  • There is still debate as to which method is better and the diagnostic value and necessity of combining the two methods remains unclear.

    Comparison of Conventional Smears with Liquid Preparations and Their Combined Use in Thyroid Cytopathology: A Multi-Institutional Study · 2026 · DOI

  • Its biological mechanisms and optimal management strategies warrant further investigation.

    Targeted Therapy-Induced Erythrocytosis in Thyroid Cancers: An Underrecognized Safety Signal from a Retrospective Study · 2026 · DOI

  • While the heritability to NMTC is among the highest of all cancers, the genetic determinants among NMTC families are not well understood.

    Identification of Rare Noncoding Variants in Familial Nonmedullary Thyroid Carcinoma · 2026 · DOI

  • However, progress in understanding MTC biology is limited by the lack of reliable in vivo and in vitro models.

    Patient-Derived in Vitro Models Reveal Insights into Medullary Thyroid Cancer Microenvironment and Resistance to Tyrosine Kinase Inhibitors · 2026 · DOI

  • However, prospective data supporting surveillance de-escalation and discharge to primary care (PC) after an excellent response (ER) is lacking.

    Prospective Evaluation of Follow-Up De-Escalation to Primary Care in Differentiated Thyroid Cancer with Excellent Response to Therapy · 2026 · DOI

  • However, TUS follow-up rates for ITNs and their drivers in routine practice remain unclear.

    What Happens after an Incidental Thyroid Nodule? Patterns of Thyroid Ultrasound Use and Downstream Evaluation · 2026 · DOI

  • Although intratumoral calcification is a common feature of papillary thyroid carcinoma (PTC), its impact on RFA efficacy remains unclear.

    Radiofrequency Ablation of Calcified Papillary Thyroid Microcarcinoma: Long-Term Imaging Evolution and Clinical Outcomes · 2026 · DOI

  • The molecular features underlying this distinct clinical behavior remain unclear.

    Distinct molecular profiles of indeterminate and malignant thyroid nodules in patients under 21 years of age · 2026 · DOI

  • DKK1 has been associated with progression and poor prognosis in different types of tumors; however, its role in thyroid cancer is still not well defined, and a better characterization is needed.

    Dickkopf-1 (DKK1) controls papillary and follicular thyroid cancer growth · 2026 · DOI

  • Cathepsin S (CTSS), a lysosomal cysteine protease, has been implicated in several malignancies, yet its role and regulation in PTC remain unclear.

    TCF4-driven cathepsin S promotes papillary thyroid carcinoma via PI3K/AKT/mTOR · 2026 · DOI

  • We recently identified TIMELESS as one of the upregulated core circadian clock genes during thyroid cancer dedifferentiation, but its expression and significance in thyroid cancer remain unclear.

    A TIMELESS link to dedifferentiation in thyroid cancer · 2025 · DOI

  • Although desmoplasia negativity has emerged as a powerful marker of node-negative disease, its clinical utility in hereditary MTC remains ill-defined.

    Forgoing node dissection for desmoplasia-negative hereditary medullary thyroid cancer · 2026 · DOI

  • These results identify previously under-recognised innate immune cell population and associated transcriptomic features, which suggest new mechanisms to target immune treatments in PTC refractory to other therapies.

    Myeloid landscape of BRAF-mutant papillary thyroid cancer and thyroiditis · 2026 · DOI

  • Further studies are needed to investigate the underlying biological mechanisms of the observed associations, - The development of new therapeutic strategies targeting the SERPINA1-associated SOX4–FN1 epithelial program may be a promising area of research, - Investigation of the role of other genes and pathways in PTC progression and lymphatic…

    A SERPINA1-associated SOX4–FN1 epithelial program linked to lymphatic endothelial responses in aggressive papillary thyroid carcinoma · 2026 · DOI

  • Investigate the relationship between UBB and thyroid cancer, - Study the mechanism of loss of calcitonin expression in calcitonin-negative MTCs, - Examine the role of UBB in tumor…

    Medullary Thyroid Carcinoma Without Calcitonin: A Case Linking Ultimobranchial Bodies to Tumor Evolution · 2025 · DOI

  • Erythrocytosis represents an underrecognized, early, recurrent, and indolent adverse event of antiangiogenic and targeted therapies, particularly RET i, in advanced thyroid cancer.

    Targeted Therapy-Induced Erythrocytosis in Thyroid Cancers: An Underrecognized Safety Signal from a Retrospective Study · 2026 · DOI

Most-cited papers in Thyroid Cancer Diagnosis and Treatment

Most recent work

Find a gap in your own Thyroid Cancer Diagnosis and Treatment sub-topic

This page shows what the Thyroid Cancer Diagnosis and Treatment literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 7.9M-paper local library and writes the gaps from its rows.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
4,200 open questions
Dementia and Cognitive Impairment Research
2,789 open questions
Substance Abuse Treatment and Outcomes
2,285 open questions
Cancer Immunotherapy and Biomarkers
2,273 open questions
Liver Disease Diagnosis and Treatment
2,102 open questions
Sports Performance and Training
1,952 open questions
Parkinson's Disease Mechanisms and Treatments
1,915 open questions
Mosquito-borne diseases and control
1,849 open questions
Open questions raised by papers listed on this page include: (1) Although genetic drivers such as BRAF and TP53 mutations are implicated, the mechanisms underlying this transition remain poorly understood (“Embryonic reprogramming drives anaplastic transformation in thyroid carcinoma”, 2026); (2) The extent of central and lateral neck dissection remains controversial, with recommendations largely derived from small series (“Primary Tumor Location and Lymphatic Spread in Papillary Thyroid Carcinoma”, 2026); (3) How tumor epithelial programs relate to the lymphatic microenvironment remains unclear (“A SERPINA1-associated SOX4–FN1 epithelial program linked to lymphatic…”, 2026); (4) The efficacy and mechanism of the most potent TMP derivatives against thyroid cancer (TC) remain unclear (“A novel tetramethylpyrazine derivative inhibits thyroid cancer progression by…”, 2026); (5) Little is known about patients’ experiences of radioiodine, yet negative beliefs about other novel treatments can influence adherence to precautionary behaviors and side effect experience post treatment (“Precautionary Behaviors and Side Effects after Radioiodine for Thyroid Disease:…”, 2026). 737 gap statements have been mined from Thyroid Cancer Diagnosis and Treatment papers in our 7.9M-paper local library, which holds 2,998 papers on the topic; the gaps come from whichever of those papers state one. They are mostly the research gaps the authors state and the papers' abstracts, plus future-work, limitations and challenges passages. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 1,100,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? Acceptance odds for top, mid and open/emerging journals, in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck for prior publication across 7 sources and our local library.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

How Pre-Check worksHow AI Review works

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.